Medable and MASI Capturing Rich Subjective and Data
PALO ALTO, Calif. - Medable Inc. the leading technology provider for modern clinical trials, has announced a partnership with industry leader Masimo (NASDAQ: MASI) to introduce the use of high-quality medical-grade wearable devices in clinical research. Masimo’s pulse oximeter technology, which has been trusted by clinicians for over 25 years to monitor millions of patients annually, will now enable more patients to participate in clinical trials with reduced burdens.
Masimo’s pulse oximeter technology has gained widespread recognition among medical professionals for its accuracy and reliability. By leveraging this technology in clinical trials, Medable aims to capture both subjective and data to enhance the accuracy and depth of clinical research.
Traditionally, the requirement for in-person visits and continuous monitoring has limited the number of patients participating in clinical trials. With the integration of Masimo’s wearable devices, patients can now participate in trials without the constraints of frequent in-person visits, allowing for a larger and more diverse population to be included in research studies.
The partnership between Medable and Masimo aligns with the evolving landscape of clinical research, which is increasingly relying on digital solutions to collect comprehensive and real-time data. By leveraging wearable devices, clinical trials can become more patient-centric, enabling participants to provide data from the comfort of their own homes. This approach not only improves participant experience but also increases efficiency and reduces costs for both researchers and patients.
It is important to note that Masimo has reported a decrease in revenue for the first quarter of 2024 compared to the previous year, with a decline of -12.77%. However, this decrease was faster than the overall decrease observed among Masimo’s competitors, which stood at -10.39% during the same period. Despite the revenue decline, Masimo achieved higher profitability than its competitors, with a net margin of 3.84%.
In conclusion, Medable’s partnership with Masimo to incorporate best-in-class wearable devices in clinical research represents a significant advancement in the field. By leveraging Masimo’s trusted pulse oximeter technology, more patients can participate in clinical trials, thereby increasing the diversity and size of study populations. The digital integration of wearable devices not only enhances data collection but also improves the overall experience for participants, making clinical trials more accessible and efficient.
Comments